Evidence Table H-6b. Local wound applications observational studies quality rating

| **Author Year Country** | **(1) Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?** | **(2) Were the groups comparable at baseline on key prognostic factors (e.g., by restriction or matching)?** | **(3) Did the study maintain comparable groups through the study period?** | **(4) Did the study use accurate methods for ascertaining exposures and potential confounders?** | **(5) Were outcome assessors and/or data analysts blinded to the exposure being studied?** | **(6) Did the article report attrition?** | **(7) Did the study perform appropriate statistical analyses on potential confounders?** | **(8) Is there important differential loss to follow-up or overall high loss to follow-up?** | **(9) Were outcomes pre-specified and defined, and ascertained using accurate methods?** | **Quality** | **Funding Source** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Danon, 1997121 | Yes | No | Unclear | No | Unclear | No | No | Unclear | Unclear | Poor | NR |
| Harding, 1996115  US | Unclear | NA | NA | NA | No | No | NA | Unclear | Unclear | Poor | Advance Biofactures Corp |
| Hindryckx, 1990116  Belgium | Unclear | NA | NA | NA | No | No | NA | No | Unclear | Poor | NR |
| Meaume, 200788 France | Unclear | No | No | Unclear | Unclear | Yes | No | No | No | Fair | NR |
| Moody, 199189  US | Unclear | NA | NA | Unclear | No | Yes | NA | Yes | No | Poor | NR |
| Narayanan, 2005117  US | NA (retrospective) | Yes | NA | Yes | NA (retrospective) | NA (retrospective) | Yes | No | Yes | Fair | NR |

| Evidence Table H-6b. Local wound applications observational studies quality rating | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author Year Country | (1) Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)? | (2) Were the groups comparable at baseline on key prognostic factors (e.g., by restriction or matching)? | (3) Did the study maintain comparable groups through the study period? | (4) Did the study use accurate methods for ascertaining exposures and potential confounders? | (5) Were outcome assessors and/or data analysts blinded to the exposure being studied? | (6) Did the article report attrition? | (7) Did the study perform appropriate statistical analyses on potential confounders? | (8) Is there important differential loss to follow-up or overall high loss to follow-up? | (9) Were outcomes pre-specified and defined, and ascertained using accurate methods? | Quality | Funding Source |
| Parnell, 200590  Country not reported | No | No | No | Unclear | Unclear | Yes | No | No | Unclear | Poor | NR |
| Sherman, 1995118  US | Yes | NA | NA | No | No | Yes | Unclear | Yes | Yes | Poor | Spinal Cord Research Foundation & CA Paralyzed Veterans of America |
| Sherman, 2002119  US | No | No | No | Yes | No | No | No | No | Yes | Poor | Paralyzed Veterans of America, Andrus Foundation |
| Stoker, 199091  UK | No | Unclear | Unclear | Unclear | No | Yes | Unclear | Yes | Yes | Poor | Coloplast LTD |
| Viamontes, 200392  US | Yes | No | No | Unclear | No | NA (retrospective) | No | NA (retrospective) | Unclear | Poor | NR |
| Wang, 2010120  China | No | Yes | Yes | Unclear | No | Yes | No | No | Yes | Poor | National Natural Science Foundation of China |
| Zuloff-Shani, 2010134  Israel | Yes | No | Unclear | Unclear | No | No | No | No | No | Poor | Rosetree Trust |